79218
Off
Valiant Lab IPO

Valiant Laboratories IPO

  • Status: Closed
  • RHP:
  • ₹ 13,965 / 105 shares

    Minimum Investment

IPO Details

  • Open Date

    27 Sep 2023

  • Close Date

    03 Oct 2023

  • IPO Price Range

    ₹ 133 to ₹ 140

  • IPO Size

    ₹ 152.46 Cr

  • Listing Exchange

    BSE, NSE

  • Listing Date

    09 Oct 2023

With just a few clicks, Invest in IPOs!

+91

By proceeding, you agree to all T&C*

hero_form

Valiant Laboratories IPO Subscription Status

Last Updated: 03 October 2023 6:13 PM by 5Paisa

Valiant Laboratories Limited IPO is all set to open from 27th September to 3rd October 2023. The company is involved in the business of pharmaceutical ingredient manufacturing with a focus on manufacturing Paracetamol. The IPO includes a fresh issue of 10,890,000 equity shares worth ₹152.46 cr. The share allotment date is 5th October, and the IPO will be listed on 9th October on the stock exchanges. The price band is ₹133 to ₹140 per share and the lot size is 105 shares.    

Unistone Capital Pvt Ltd is the book-running lead manager for this IPO, while Link Intime India Private Ltd is the registrar. 

Objectives of Valiant Lab IPO:

●    To invest in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) for part-financing its capital expenditure requirements in relation to the setting up of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (Proposed Facility).
●    To invest in VASPL to fund its working capital requirements.
●    Fund general corporate purposes.
 

Valiant Lab IPO Video:

 

Established in 1980, Valiant Laboratories Limited is involved in the business of pharmaceutical ingredient manufacturing with a focus on manufacturing Paracetamol.

The company has its manufacturing facility in Palghar, Maharashtra, spanning over 2,000 square meters of land. This facility has an annual production capacity of 9,000 metric tons. Additionally, the company houses an R&D center featuring an analytical laboratory and resources dedicated to product development. 

As of April 30, 2023, Valiant Laboratories employs a workforce of 86 individuals. The company also possesses Good Manufacturing Practices (GMP) for the production and distribution of bulk drugs/API, along with ISO 9001:2015 certification.

Peer Comparison
●    Granules India Ltd
●    Jagsonpal Pharmaceuticals Ltd
●    Alkyl Amines Chemicals Ltd
●    Laxmi Organic Industries Ltd

For More Information:
Webstory on Valiant Laboratories IPO

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY23 FY22 FY21
Revenue 333.91 291.52 182.36
EBITDA 35.09 42.32 50.00
PAT 28.99 27.49 30.59
Particulars (in Rs. Crores) FY23 FY22 FY21
Total Assets 212.76 181.81 106.31
Share Capital 32.56 16.28 10.50
Total Borrowings 112.26 110.35 17.73
Particulars (in Rs. Crores) FY23 FY22 FY21
Net cash generated from / (used in) operating activities 22.96 2.25 9.10
Net cash from / (used in) investing activities -21.18 -12.24 -16.67
Net cash flow from / (used in) financing activities -1.53 6.18 11.43
Net increase (decrease) in cash and cash equivalents 0.24 -3.80 3.87

Strengths

1.    The company has reported strong financial performance.
2.    The company is working on reducing dependence on the import of raw materials.
3.    The company’s Manufacturing Facility is strategically located near JNPT (Nhava Sheva) Port, Maharashtra and its registered office at Mulund West, Mumbai, Maharashtra, which ensures that it has ready access to port facilities and is able to expediently import raw materials and export products in a cost-efficient manner. 
4.    Highly experienced Management team.
 

Risks

1.    The company solely focuses on manufacturing the paracetamol. Thus, any changes in its demand can adversely affect the business. 
2.    The majority of the operative income is derived from the domestic market.
3.    Subject to government regulations.
4.    Operates in an intensely competitive industry. 
5.    Pricing pressure from customers may affect the business. 
6.    Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing and reimbursement could adversely affect the pricing and demand for the company’s products.
7.    Restrictions on the import of raw materials may impact the business and results of operations.
8.    Higher working capital requirements.  
 

Will You Apply for Valiant Laboratories IPO?

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

FAQs

The minimum lot size of Valiant Laboratories IPO is 105 shares and the investment required is ₹13,965.

The price band of Valiant Laboratories IPO is ₹133 to ₹140.

Valiant Laboratories IPO is open from 27th September to 3rd October 2023.
 

The size of Valiant Laboratories IPO is ₹152.46 cr, which includes a fresh issue of 10,890,000 equity shares. 

The share allotment date of Valiant Laboratories IPO is 5th of October 2023.

The Valiant Laboratories IPO will be listed on 9th of October 2023.

Unistone Capital Pvt Ltd is the book-running lead manager for Valiant Laboratories IPO.

Valiant Laboratories plans to utilize the raised capital from IPO to:

1.    To invest in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) for part-financing its capital expenditure requirements in relation to the setting up of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (Proposed Facility).
2.    To invest in VASPL to fund its working capital requirements.
3.    Fund general corporate purposes.
 

To apply for Valiant Laboratories IPO, follow the steps given below:

●    Login to your 5paisa account and select the issue in the current IPO section    
●    Enter the number of lots and the price at which you wish to apply for the Valiant Laboratories IPO.    
●    Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    
●    You will receive a mandate notification to block funds in your UPI app.